Press release MHRA approves GLP –one receptor agonist semaglutide to cut back hazard of great heart problems in obese or overweight Older people Semaglutide is the first weight-loss drug accredited in the united kingdom like a preventative therapy for anyone with recognized cardiovascular diseaseimproved danger of lower blood sugar (hypoglycemia)